FINNENCE ▪ THE WIRE FILE
THE WIRE · № 70989
News■ Unclear/unknown
Psilera Greenlit to Initiate Phase 2 of NIH Grant for Alcohol Use Disorder
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-08 12:15 UTC
LAST UPDATE2026-10-08 12:15 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
NIH grant progress for a private psychedelics firm signals drug-class momentum but no listed exposure.
Psychedelic drug-class momentum, private company only
CATALYST TO WATCH
Phase 2 data readouts for the program
MAIN RISK
Early-stage, private, no ticker exposure
FULL DISPATCH
Government-backed research into next-generation psychedelics and neuroplastogens for addictive disorders underscores the continued momentum behind this promising drug class. TAMPA, Fla., Oct. 8, 2026 /PRNewswire/ -- Psilera Inc. ("Psilera"), a leading biopharmaceutical company pioneering...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
GLP-1s could offer unexpected relief from back and knee pain, but doctors urge caution2026-10-08 12:30 UTC
GLP-1s could offer unexpected relief from back and knee pain, but doctors urge caution2026-10-08 12:30 UTC
←CORRELATIONshares Healthcare
Nuevocor Doses First Patient in SUNBEAM-LMNA Phase 1/2 Trial and Receives FDA Fast Track Designation for NVC-001 in LMNA Dilated Cardiomyopathy2026-10-08 11:30 UTC
Nuevocor Doses First Patient in SUNBEAM-LMNA Phase 1/2 Trial and Receives FDA Fast Track Designation for NVC-001 in LMNA Dilated Cardiomyopathy2026-10-08 11:30 UTC
←CORRELATIONshares Healthcare
Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology2026-10-08 11:30 UTC
Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology2026-10-08 11:30 UTC
←CORRELATIONshares Healthcare
Aragen Life Sciences begins Operations at OneHP, an Integrated High-potency Platform in Hyderabad, India2026-10-08 11:30 UTC
Aragen Life Sciences begins Operations at OneHP, an Integrated High-potency Platform in Hyderabad, India2026-10-08 11:30 UTC
←CORRELATIONshares Healthcare
Keenova Announces New Presentations at the Sexual Medicine Society of North America Annual Meeting2026-10-08 11:30 UTC
Keenova Announces New Presentations at the Sexual Medicine Society of North America Annual Meeting2026-10-08 11:30 UTC
←CORRELATIONshares Healthcare
Saol Therapeutics Announces Completion of Enrollment in Pivotal Phase III BEACON Trial of SL1002 for the Treatment of Chronic Pain Related to Osteoarthritis of the Knee2026-10-08 11:30 UTC
Saol Therapeutics Announces Completion of Enrollment in Pivotal Phase III BEACON Trial of SL1002 for the Treatment of Chronic Pain Related to Osteoarthritis of the Knee2026-10-08 11:30 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.